Researchers at the University of Toronto’s Faculty of Dentistry and the National Jewish Health in Denver report a new drug discovery that could be useful to combat inflammation of all varieties and shows promise in fighting acute respiratory illnesses such as COVID-19.
Called TAT CARMIL1, the drug is actually a combination of two naturally occurring peptides that, when combined, work together to penetrate a cell’s membrane in order to dampen an acute inflammatory response. In this first ex vivo study “The Leucine-Rich Repeat Region of CARMIL1 Regulates IL-1-Mediated ERK Activation, MMP Expression, and Collagen Degradation”, published in Cell Reports, the peptide reduced collagen degradation by up to 43 percent.
